Tag: oral immunotherapy (OIT)

Palforzia Capsules with Logo

Aimmune Provides FDA Mandated Program for Patients Considering Treatment of Peanut...

The FDA seeks to mitigate risks associated with treatment by mandating a program that must be followed by patients, prescribers, pharmacies, and healthcare settings.
Tablets

Study: Co-Treatments Like Antihistamines and Probiotics Make Peanut OIT Success in...

“These findings suggest that slight modifications to treatment protocols could play a key role in substantially improving treatment safety.”
AAAAI Palforzia Release

What You Need to Know About the First Peanut Allergy Treatment...

Information for patients and their families about this new treatment option, what it means, and why it won’t be right for everyone.
Palforzia

FDA Approves Aimmune’s PALFORZIA as First Treatment for Peanut Allergy

Palforzia is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.
AAAAI Logo + Palforzia

AAAAI Addresses What Patients and Their Families Need to Know About...

As the FDA moves closer to approving the first food allergy treatment, the AAAAI seeks to help patients and their families understand the realities surrounding OIT.
Peanuts

Study: Few People with Peanut Allergy Tolerate Peanut after Stopping OIT

Continuing with a modest dose confers more protection, NIH-funded study finds.
Paliforzia (AR101)

FAQ for Palforzia, the First FDA Approved Therapy for Food Allergy

What it is, what it treats, who it is for, how it is used, et al.
Patient Undergoing SLIT

New Peanut Allergy Treatment Passes Phase 2 Trial, Shows Effectiveness and...

UNC School of Medicine researchers show that tiny under-the-tongue doses of peanut protein can offer safe and substantial protection against peanut allergy.
Eggs

Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for...

AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.